U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950215) titled 'A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia' on Nov. 15.
Brief Summary: This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).
Study Start Date: Feb. 01, 2027
Study Type: INTERVENTIONAL
Condition:
Anemia Due to Chronic Kidney Disease
Intervention:
DRUG: AND017 capsules
AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patient...